1.	Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1216, NCI-2013-00500, U10CA021661, NCT01810913
2.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
3.	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Phase: Phase III Type: Treatment Status: Active Age: 18 to 72 Sponsor: Pharmaceutical / Industry Protocol IDs: CS001P3, 2010-019952-35, NCT01265849
4.	LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.131, 2011-000392-14, NCT01345669
5.	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
6.	A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: X90003, NCT00660218
7.	A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
8.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
9.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
10.	Vitamin D - Celecoxib Therapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CLIN-003-09S, NCT00953849
11.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
12.	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 100180, 10-D-0180, NCT01195922
13.	Study of PX-866 and Docetaxel in Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
14.	A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1761-09, NCT01283334
15.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
16.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
17.	A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1266, NA_00074085, NCT01732640
18.	A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 254, NCT01744340
19.	Phase II Trial Evaluating Elimination of Radiation Therapy Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 07-0142 / 201106342, NCT00593840
20.	Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 06-120, NCT00798655
21.	Preoperative Treatment With Cetuximab and/or IMC-A12 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0342, NCT00957853
22.	Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-083, NCT00968435
23.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
24.	Preoperative Soy Isoflavone Supplementation in the Prevention of Head and Neck Squamous Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 to 80 Sponsor: Other Protocol IDs: UMCC 2009.008, HUM%26957, NCT01028001
25.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075